During the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition, CancerNetwork® spoke with Andre Goy, MD, about how a multidisciplinary care team is imperative to administering CAR T-cell therapy to patients with hematologic malignancies quickly, and managing any toxicities.
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andre Goy
Unmet Needs in Diffuse Large B-Cell Lymphoma
Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned, it is important to refer those patients to this option because nothing else cures them in that setting.
DLBCL: Treatment Considerations in the Second Line
Transcript: Andre H. Goy, MD: I want to go back to wrap up this conversation. In the second-line setting, now that we have multiple drugs approved, when you see a patient—I know we touched a little on this as we discussed every topic—how do you summarize for our audience how to decide what treatment to give to whom? Andrew Ip, MD: If I don’t say it enough, I’ll say it again.
L-MIND Trial: Tafasitamab plus Lenalidomide in Relapsed/Refractory DLBCL
Transcript: Andre H. Goy, MD: Let’s move back into the relapsed/refractory setting, where there has been a plethora of novel agents approved. And we’ll talk more about CAR [chimeric antigen receptor] T-cell therapy in a second, but it was the L-MIND study [NCT02399085]. [Talk about] the L-MIND study. There was a long-term follow-up that showed durable responses. What do you think of these data?
ZUMA-7: Axi-Cel in Patients with Relapsed/Refractory DLBCL
Transcript: Andre H. Goy, MD: Back to the CAR [chimeric antigen receptor] T cells. We talked a little bit about this, but where does CAR T-cell therapy currently fit in your paradigm, given the fact that we have the second line and third line? If you can just give a quick overview.
Future Outlook of Mantle Cell Lymphoma Treatment
Transcript: Andre H. Goy, MD: In the frontline setting, that’s where the paradigm is going to shift even more, in that the ability to do NGS [next-generation sequencing]—now we do this routinely—allows you to detect abnormalities such as TP53 mutation and others, particularly complex karyotype in the frontline setting. About one-third of these patients should either be on a clinical trial, or in our institution and academic center we treat them with a nonchemotherapy option.
Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape
Transcript: Andre H. Goy, MD: Generally speaking, how has the treatment paradigm of large cell lymphoma shifted in recent years? In particular, how many patients develop relapsed/refractory disease? Andrew Ip, MD: It’s probably easier to answer the second question. There are already great statistics from the post-rituximab era from the early 2000s that we’re still not perfect.
Second-Line Therapy Options for Relapsed/Refractory MCL
Transcript: Andrew Ip, MD: Now that we have all these updates, exciting research, and further studies to probably do, what are you doing now in a patient in front of you in the second-line setting, especially with relapsed mantle cell lymphoma? What are you telling them is their best option right now with the available data on pirtobrutinib, brexu-cel [brexucabtagene autoleucel], venetoclax combinations, and other BTK inhibitors? Andre H.
CAR T-Cell Therapy in Mantle Cell Lymphoma
Transcript: Andrew Ip, MD: The next couple of questions all relate around CAR T and cellular therapies. The first question to you or comment is about the ZUMA-2 trial, which I know you know all about. The 3-year updates on brexu-cel [brexucabtagene autoleucel] and mantle cell was presented at ASH [American Society of Hematology] and ASCO [American Society of Clinical Oncology] last year. Andre H.
BRUIN Trial: Pirtobrutinib for Patients With MCL
Contemporary Concepts Awareness Month Interactive Tools Nurse Practitioners/Physician's Assistants Partners Sponsored
Andre H. Goy, MD, on Unresolved Questions in Mantle Cell Lymphoma
Andre H. Goy, MD, discussed the most pressing unresolved questions in the current treatment of MCL in an interview with the journal ONCOLOGY. “It’s time to dissect MCL and account for its molecular heterogeneity when refining our treatment.” Andre H.
Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia
Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center - Episode 8 Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia Dr Lori Leslie provides an overview of key clinical trial data on the use of CAR T-cell therapy in chronic lymphocytic leukemia.
Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma
Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center - Episode 7 Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma Drs Goy and Leslie converse on the use of CAR T-cell therapy in acute lymphoblastic lymphoma, the first approved treatment for ALL.
CAR-T Therapies in the Follicular Lymphoma Treatment Landscape
Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center - Episode 6 CAR-T Therapies in the Follicular Lymphoma Treatment Landscape Lori Leslie, MD, explains how CAR T-cell therapy fits into follicular lymphoma treatment sequencing, highlighting data from the ZUMA-5 trial.
Managing Toxicities Associated with CAR-T Therapy in LBCL
Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center - Episode 4 Managing Toxicities Associated with CAR-T Therapy in LBCL Dr Andrew Ip explains the major toxicities of CAR T-cell therapy in patients with large B-cell lymphoma and how to manage them.
Selecting the Appropriate Patients and Monitoring Responses to CAR-T Therapy in LBCL
EP. 2 : Selecting the Appropriate Patients and Monitoring Responses to CAR-T Therapy in LBCL
The cancer moonshot: Here's how we get there
A generation ago we spoke of cancer in hushed tones. We whispered about the suspected "Big C," diagnoses were kept secret, and that was that. Our collective will to tackle this killer changed the game: death rates dropped nearly 30 percent in a generation. Today, 16 million Americans are cancer survivors. It's time to recommit to saving more lives as President Biden has proposed in his plan to reignite the Cancer Moonshot.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang Honoraria: Janssen Research & Development, Dava Oncology, OM Pharmaceutical Industries, AstraZeneca, CAHON, Hebei Cancer Prevention Federation, Mumbai Hematology Group, Acerta Pharma, Chinese Anti-Cancer Association, BeiGene, Chinese Medical Association, Clinical Care Options, Epizyme, Imedex, Kite, a Gilead company, Miltenyi Biomedicine, Moffit Cancer Center, Newbridge Pharmaceuticals, Physicans' Education Resource, Scripps Health, The First Affiliated Hospital of Zhejiang...
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
DOI: 10.1200/JCO.21.02370 Journal of Clinical Oncology - published online before print June 4, 2022
FDA approves Yescarta as second-line therapy for large B-cell lymphoma
April 04, 2022 4 min read Source/Disclosures Disclosures: Forman reports scientific advisory board roles with Allogene and Mustang Bio, as well as research funding from Mustang Bio. Goy reports a scientific advisory board role with Kite Pharma/Gilead Sciences. He also served as a primary investigator in other ZUMA trials. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma
ABSTRACT Introduction: While there has been an improvement in the treatment of mantle cell lymphoma (MCL) in both median progression-free survival (PFS; >7–8 years) and overall survival (OS; >10–12 years), patients with high-risk features such as high risk MIPI (mantle cell international prognostic index), high Ki-67 (≥30%), or blastoid variants still carry poor outcome with a median OS of 3 years.
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
Research article Open Access Published: 14 January 2021 Andrew Ip ORCID: orcid.org/0000-0003-0456-56181,2,3, Jaeil Ahn4, Yizhao Zhou4, Andre H. Goy5, Eric Hansen6, Andrew L. Pecora5, 5, Urszula Bednarz5, Michael Marafelias5, Ihor S. Sawczuk2,3, Joseph P. Underwood III7, David M. Walker7, Rajiv Prasad8, Robert L. Sweeney9, Marie G. Ponce9, Samuel La Capra10, Frank J. Cunningham10, Arthur G. Calise11, Bradley L. Pulver12, Dominic Ruocco13, Greggory E. Mojares14, Michael P. Eagan15, Kristy L.
Registry sheds light on vulnerability of patients with hematologic malignancies, COVID-19
December 05, 2020 3 min read Save Perspective from Perspective from Source/Disclosures Source: Wood WA, et al. Abstract 215. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020. Disclosures: Wood reports consultant roles with Teladoc/Best Doctors, honoraria from ASH Research Collaborative and research funding from Pfizer. Please see the abstract for all other researchers’ relevant financial disclosures.
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
Abstract Background: Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study
View ORCID ProfileAndrew Ip, View ORCID ProfileDonald A Berry, Eric Hansen, View ORCID ProfileAndre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk, Noa Biran, View ORCID ProfileRonaldo C Go, Steven Sperber, Julia A Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L Timmapuri, Joseph P Underwood III, Gregory Sugalski,...
Andre H. Goy, MD, MS, Discusses Extending Survival for Patients with DLBCL
December 13, 2019 Andre H. Goy, MD, MS, chairman of John Theurer Cancer Center, from Hackensack University Medical Center, discussed ways to address the challenge of extending survival for patients with diffused large B-cell lymphoma (DLBCL) who achieved a complete remission (CR) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
To the Editor: Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1,2,3,4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5].
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin Kingsley, Jerry Ping, Darrin M. Beaupre, Jutta K. Neuenburg and Jia Ruan Blood 2019 134:1024-1036; doi: https://doi.org/10.1182/blood.2018891598 Key Points The safety profile of ibrutinib, lenalidomide, and rituximab in combination was manageable in patients with relapsed/refractory DLBCL.
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell DLBCL
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin Kingsley, Jerry Ping, Darrin M. Beaupre, Jutta K.
Brentuximab vedotin, nivolumab combination appears active for Hodgkin lymphoma
ATLANTA — A combination of brentuximab vedotin with nivolumab appeared tolerable and safe among patients with relapsed or refractory Hodgkin lymphoma, according to results from a phase 1/phase 2 clinical trial presented at the ASH Annual Meeting and Exposition. An unmet clinical need remains for relapsed or refractory Hodgkin Lymphoma, despite medical advances. Alex F.
Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials
The introduction of anthracyclines into the first-generation regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in 1976 resulted in a 10-year overall survival of around 20%.1 Despite being promising in phase II testing, more complex second- and third-generation regimens did not supersede CHOP in a large phase III trial.2 A decade later, the addition of the anti-CD20 monoclonal antibody (mAb) rituximab became the first improvement over CHOP,3 initially shown in...
What will healthcare look like in 2030?
The challenge with healthcare reform has always been that incentives are misaligned: policymakers, providers, payers and patients all want different things. With so many novel therapies being developed, there has never been a more exciting time to be practising medicine, says Dr Andre Goy, Chairman and Director, Chief of Lymphoma, John Theurer Cancer Centre, Hackensack University Medical Centre.
What will healthcare look like in 2030?
With so many novel therapies being developed, there has never been a more exciting time to be practicing medicine, says Dr Andre Goy, Chairman and Director, Chief of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center. However, rising costs combined with an ageing population and an increase in non-communicable diseases means that global healthcare needs to be “fundamentally reinvented”, he argues in this interview.
POINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma
The management of mantle cell lymphoma has evolved dramatically since 1994, when the Revised European-American Lymphoma Classification recognized it as a separate disease entity. This was based not only on the distinct molecular features (hallmark t(11;14) translocation) and immunophenotype of mantle cell lymphoma but also on its distinct clinical course, with much poorer outcomes than those of other patients with so-called indolent lymphomas.
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
|
By Andre Goy, Jeremy J. Rose, Steven Rosenberg, Steven Feldman, Jennifer N. Brudno, Robert P. T. Somerville, Victoria Shi, David C. Halverson, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Alexander T. Iwamoto, Roger Kurlander, Irina Maric, Brenna G. Hansen, Jennifer S. Wilder, Bazetta Blacklock-Schuver, Frances T. Hakim, Ronald E. Gress, Daniel Fowler
|
ascopubs.org
Purpose Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andre
Contact Andre, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack